Curasight strengthened the development of its integrated uPAR-based platform during the third quarter of 2025. The company received EMA approval to initiate its first clinical study with its therapeutic radiopharmaceutical in aggressive brain cancer, while patient recruitment gained traction in the ongoing phase II study with its diagnostic platform. After the period Curasight announced further momentum in its pipeline, with the initiation of recruitment in the first clinical study investigating the company’s therapeutic platform uTREAT®. BioStock reached out to CEO Ulrich Krasilnikoff for comments.